JP2023546293A5 - - Google Patents

Info

Publication number
JP2023546293A5
JP2023546293A5 JP2023548537A JP2023548537A JP2023546293A5 JP 2023546293 A5 JP2023546293 A5 JP 2023546293A5 JP 2023548537 A JP2023548537 A JP 2023548537A JP 2023548537 A JP2023548537 A JP 2023548537A JP 2023546293 A5 JP2023546293 A5 JP 2023546293A5
Authority
JP
Japan
Prior art keywords
region
amino acid
seq
acid sequence
sequence shown
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023548537A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023546293A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2021/055311 external-priority patent/WO2022082066A1/en
Publication of JP2023546293A publication Critical patent/JP2023546293A/ja
Publication of JP2023546293A5 publication Critical patent/JP2023546293A5/ja
Pending legal-status Critical Current

Links

JP2023548537A 2020-10-18 2021-10-15 抗ｃｓｐｇ４結合剤、そのコンジュゲートおよびその使用方法 Pending JP2023546293A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063093255P 2020-10-18 2020-10-18
US63/093,255 2020-10-18
PCT/US2021/055311 WO2022082066A1 (en) 2020-10-18 2021-10-15 Anti-cspg4 binding agents, conjugates thereof and methods of using the same

Publications (2)

Publication Number Publication Date
JP2023546293A JP2023546293A (ja) 2023-11-01
JP2023546293A5 true JP2023546293A5 (enExample) 2024-10-16

Family

ID=78709534

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023548537A Pending JP2023546293A (ja) 2020-10-18 2021-10-15 抗ｃｓｐｇ４結合剤、そのコンジュゲートおよびその使用方法

Country Status (6)

Country Link
US (1) US20250213715A1 (enExample)
EP (1) EP4228704A1 (enExample)
JP (1) JP2023546293A (enExample)
CN (1) CN116782955A (enExample)
CA (1) CA3195865A1 (enExample)
WO (1) WO2022082066A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114836541B (zh) * 2022-05-23 2026-02-17 中国药科大学 一种利用尿液微囊泡蛋白作为肾癌诊断标志物的应用
KR20250079227A (ko) * 2022-10-25 2025-06-04 머크 샤프 앤드 돔 엘엘씨 엑사테칸-유래 adc 링커-페이로드, 제약 조성물, 및 그의 용도

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7662387B2 (en) * 2003-02-20 2010-02-16 Seattle Genetics Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AU2006262231B2 (en) * 2005-06-20 2013-01-24 Psma Development Company, Llc PSMA antibody-drug conjugates
KR101870555B1 (ko) * 2011-08-23 2018-06-22 로슈 글리카트 아게 T 세포 활성화 항원 및 종양 항원에 대해 특이적인 이중특이적 항체 및 이의 사용 방법
JP2014534806A (ja) * 2011-08-23 2014-12-25 ロシュ グリクアート アーゲー 抗ｍｃｓｐ抗体
WO2015012904A2 (en) * 2012-12-13 2015-01-29 Immunomedics, Inc. Antibody-sn-38 immunoconjugates with a cl2a linker
MX2015010789A (es) * 2013-02-26 2015-11-26 Roche Glycart Ag Anticuerpos anti-pcsm.

Similar Documents

Publication Publication Date Title
AU2012235817B2 (en) Antibody-drug conjugates
JP2025111463A5 (enExample)
JP2021516973A5 (enExample)
JP2021515565A5 (enExample)
JP2017510559A5 (enExample)
JP2020501531A5 (enExample)
JP2012522513A5 (enExample)
JP2025183307A5 (enExample)
JP2015509947A5 (enExample)
RU2014113304A (ru) Анти-cd40-антитела, применение и методы
JP2022533538A5 (enExample)
JP2015533781A5 (enExample)
JP2020522280A5 (enExample)
JP2022523360A5 (enExample)
CA3235789A1 (en) Cancer specific plectin-1 specific antibodies and methods of use thereof
JP2025513721A5 (enExample)
JP2020534326A (ja) イムノコンジュゲートにおけるメチオニン酸化を防止する方法
JP2024533457A5 (enExample)
JPWO2021251459A5 (enExample)
JP2024540536A5 (enExample)
EP4491632A1 (en) Ror1-targeted binding molecule and use thereof
JP2024502670A5 (enExample)
JP2022535276A5 (enExample)
KR102793781B1 (ko) Hla-g에 특이적으로 결합하는 항체 및 이의 용도
WO2026035616A1 (en) Combinations for the treatment of cancer